Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT05408845
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
146 Enrollment(s)
154 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Salivary Gland Carcinoma


Recurrent Salivary Gland Carcinoma


Stage III Major Salivary Gland Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Unresectable Salivary Gland Carcinoma
COMPLETED
NCT07838987
A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
196 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Healthy
RECRUITING
NCT07704918
Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
Melanoma
RECRUITING
NCT07619521
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
31 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Pancreatic Ductal Adenocarcinoma


Metastatic Pancreatic Ductal Adenocarcinoma


Stage III Pancreatic Cancer AJCC v8


Stage IV Pancreatic Cancer AJCC v8


Unresectable Pancreatic Ductal Adenocarcinoma
TERMINATED
NCT06718179
Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents
130 Enrollment(s)
3 Study location(s)
INTERVENTIONAL (PHASE4)
Acute Coronary Syndrome
ACTIVE_NOT_RECRUITING
NCT04784715
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
1,157 Enrollment(s)
283 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer; HER2-positive; Metastatic
ACTIVE_NOT_RECRUITING
NCT05048797
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
454 Enrollment(s)
130 Study location(s)
INTERVENTIONAL (PHASE3)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
WITHDRAWN
NCT07428044
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
0 Enrollment(s)
10 Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer


Non-small Cell Lung Cancer Stage II


Non-Small Cell Lung Cancer Stage IIIA


Non-Small Cell Lung Cancer Stage IIIB